treatment approaches for patients with tp53m aml ineligible for high intensity chemotherapy
Published 1 year ago • 171 plays • Length 1:39Download video MP4
Download video MP3
Similar videos
-
2:23
improving treatment for patients with tp53-mutated myeloid malignancies
-
3:56
treatment approaches for patients with tp53-mutated mcl
-
1:27
treatment options for patients with tp53-mutated aml
-
1:33
the current guidelines and therapies for tp53-mutated mds and aml
-
3:19
an overview of novel treatment approaches in tp53-mutated aml
-
1:26
updates in the treatment landscape of p53-mutated aml/mds
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
1:27
tp53-aberrant mcl: challenges and treatment approaches
-
1:13
the challenges of treating patients with mpns who possess a tp53 mutation
-
1:08
novel strategies to target p53-mutant hematological malignancies
-
0:44
unmet needs in aml: tp53 mutations and maintenance therapy
-
1:17
combination therapy for the treatment of aml
-
2:27
addressing the unmet needs for patients with tp53-mutated aml
-
1:40
new therapeutic approaches targeting xpo1-overexpression in tp53-mutated myeloid malignancies
-
0:58
optimizing treatment for ph all: tkis combined with chemotherapy followed by transplantation
-
2:11
efficacy of parp inhibitors in the treatment of aml
-
1:04
continuous treatment with flt3 inhibitors for patients with flt3-mutated aml undergoing allosct
-
1:23
the current treatment landscape for patients with t-cell prolymphocytic leukemia